|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...7891011121314151617...6566» |
- ||| Trial completion: TailoredT: Prospective Study to Characterize Host-pathogen Related Factors in Hospitalized and ED Patients With LRTI and/or Sepsis (clinicaltrials.gov) - Jan 13, 2017
P=N/A, N=1200, Completed, Sponsor: MeMed Diagnostics Ltd.
Active, not recruiting --> Completed
- Trial completion: CORAL: Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli (clinicaltrials.gov) - Jan 13, 2017
P=N/A, N=44, Completed, Sponsor: NIZO Food Research
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P1 trial: Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine (clinicaltrials.gov) - Jan 11, 2017
P1, N=36, Completed, Sponsor: Research Institute for Biological Safety Problems
- ||| aztreonam / Generic mfg.
Trial completion: Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients (clinicaltrials.gov) - Jan 11, 2017
P=N/A, N=510, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Deltyba (delamanid) / Otsuka
Trial completion: Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis (clinicaltrials.gov) - Jan 10, 2017
P3, N=511, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Shanchol (oral cholera vaccine) / Sanofi
Enrollment closed: Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine (clinicaltrials.gov) - Jan 10, 2017
P1/2, N=840, Active, not recruiting, Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- Enrollment change, Trial withdrawal, IO biomarker, Pneumococcal vaccines: Antibodies and Memory Cells Role After Different Pneumococcal Vaccines in HIV Adults (clinicaltrials.gov) - Jan 10, 2017
P=N/A, N=0, Withdrawn, Sponsor: University of Siena
Not yet recruiting --> Active, not recruiting N=250 --> 0 | Active, not recruiting --> Withdrawn
- cefixime / Generic mfg., azithromycin / Generic mfg.
Enrollment closed, Trial primary completion date: Cefixime / Azithromycin pK Study (clinicaltrials.gov) - Jan 9, 2017
P1, N=10, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=250 --> 0 | Active, not recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Dec 2016
- Cubicin (daptomycin) / Merck (MSD)
Trial primary completion date: IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB (clinicaltrials.gov) - Jan 6, 2017
P4, N=50, Recruiting, Sponsor: Sharp HealthCare
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Dec 2016 Trial primary completion date: May 2016 --> Aug 2017
- |||| Trial primary completion date: Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen (clinicaltrials.gov) - Jan 6, 2017
P3, N=1080, Recruiting, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Trial primary completion date: May 2016 --> Aug 2017 Trial primary completion date: Nov 2016 --> Jun 2017
- Trial primary completion date: Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment (clinicaltrials.gov) - Jan 6, 2017
P4, N=393, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial primary completion date: Nov 2016 --> Jun 2017 Trial primary completion date: Oct 2016 --> Jul 2017
- vancomycin / Generic mfg.
Phase classification: Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project (clinicaltrials.gov) - Jan 5, 2017
P1, N=399, Completed, Sponsor: Mayo Clinic
Trial primary completion date: Oct 2016 --> Jul 2017 Phase classification: P=N/A --> P1
- colistin sulphate / Generic mfg.
New trial: Clinical Usefulness of Therapeutic Drug Monitoring of Colistin in Patients Treated With Colistin. (clinicaltrials.gov) - Jan 4, 2017
P=N/A, N=60, Recruiting, Sponsor: Seoul National University Hospital
- ||||| New P2 trial: Goldeneye: Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240) (clinicaltrials.gov) - Jan 4, 2017
P2, N=148, Not yet recruiting, Sponsor: NicOx
- | niclosamide topical (ATx 201) / UNION Therap
New P1/2 trial: Evaluation of ATx201 as a Topical Antibiotic Agent (clinicaltrials.gov) - Jan 4, 2017
P1/2, N=76, Recruiting, Sponsor: AntibioTx ApS
- New trial: STI Screening as a Combined HIV Prevention Platform for MSM in Peru (clinicaltrials.gov) - Jan 3, 2017
P=N/A, N=150, Not yet recruiting, Sponsor: University of California, Los Angeles
- |||||||||| Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini
New P3 trial: TANGOIII: A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (clinicaltrials.gov) - Dec 30, 2016
P3, N=790, Not yet recruiting, Sponsor: The Medicines Company
- TicoVac (tick-borne encephalitis vaccine, whole Virus inactivated) / Pfizer
Enrollment change, Trial termination, Trial primary completion date: Vaccine Study for Tick-Borne Encephalitis Virus (TBEV) (clinicaltrials.gov) - Dec 28, 2016
P2, N=26, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P=N/A --> P1 N=160 --> 26 | Recruiting --> Terminated | Trial primary completion date: Nov 2020 --> Dec 2016; Manufacturer discontinued support of the study
- |||| Trial primary completion date: Phase III Clinical Study of Efficacy and Safety of Vaccae (clinicaltrials.gov) - Dec 28, 2016
P3, N=10000, Active, not recruiting, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
N=160 --> 26 | Recruiting --> Terminated | Trial primary completion date: Nov 2020 --> Dec 2016; Manufacturer discontinued support of the study Trial primary completion date: Jan 2016 --> Apr 2017
- Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
Trial primary completion date: Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia. (clinicaltrials.gov) - Dec 27, 2016
P=N/A, N=1, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Jan 2016 --> Apr 2017 Trial primary completion date: Oct 2016 --> Nov 2018
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Phase classification: Pneumococcal Reference Standard (clinicaltrials.gov) - Dec 27, 2016
P1, N=250, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Oct 2016 --> Nov 2018 Phase classification: P=N/A --> P1
- levofloxacin / Generic mfg.
Phase classification: Enteroaggregative E.Coli (EAEC) (clinicaltrials.gov) - Dec 27, 2016
P1, N=5, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P=N/A --> P1 Phase classification: P=N/A --> P1
- ||| 514G3 / XBiotech
Enrollment closed, Trial primary completion date: A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus (clinicaltrials.gov) - Dec 23, 2016
P1/2, N=52, Active, not recruiting, Sponsor: XBiotech, Inc.
Phase classification: P=N/A --> P1 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jan 2017
- Trial primary completion date, Surgery: SREENSTAPH2: Study of Staphylococcus Aureus Colonization of the Posterior Nasal Cavity in Patients Undergoing Otorhinolaryngologic Surgery (clinicaltrials.gov) - Dec 23, 2016
P=N/A, N=160, Recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jan 2017 Trial primary completion date: Nov 2016 --> Oct 2017
- | Gohibic (vilobelimab) / Staidson Biopharma, InflaRx
New P2 trial: Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Dec 22, 2016
P2, N=12, Not yet recruiting, Sponsor: InflaRx GmbH
- Clinical: Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: A Pilot RCT (clinicaltrials.gov) - Dec 22, 2016
P=N/A, N=115, Recruiting, Sponsor: Sunnybrook Health Sciences Centre
Trial primary completion date: Nov 2016 --> Oct 2017 Trial primary completion date: Oct 2016 --> Mar 2017
- ||||| pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment closed: STAND: Shortening Treatment by Advancing Novel Drugs (clinicaltrials.gov) - Dec 21, 2016
P3, N=1500, Active, not recruiting, Sponsor: Global Alliance for TB Drug Development
Trial primary completion date: Oct 2016 --> Mar 2017 Suspended --> Active, not recruiting
- ||| Trial completion, Enrollment change, Biopsy: Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy (clinicaltrials.gov) - Dec 19, 2016
P=N/A, N=136, Completed, Sponsor: University of California, Irvine
Suspended --> Active, not recruiting Active, not recruiting --> Completed | N=300 --> 136
- AZD5847 / AstraZeneca
P2a data, Phase classification: Phase 2a EBA Trial of AZD5847 (clinicaltrials.gov) - Dec 19, 2016
P2a, N=75, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | N=300 --> 136 Phase classification: P2 --> P2a
- Trial initiation date: Additive Benefit of the Urine LAM Test to Current TB Diagnostics in HIV Positive Adults in Panama City, Panama (clinicaltrials.gov) - Dec 19, 2016
P=N/A, N=292, Not yet recruiting, Sponsor: University of Florida
Phase classification: P2 --> P2a Initiation date: Nov 2016 --> Mar 2017
- || Enrollment closed: A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults (clinicaltrials.gov) - Dec 16, 2016
P1, N=144, Active, not recruiting, Sponsor: Jiangsu Province Centers for Disease Control and Prevention
Initiation date: Nov 2016 --> Mar 2017 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change, Trial primary completion date: Program Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease (clinicaltrials.gov) - Dec 15, 2016
P=N/A, N=112, Completed, Sponsor: National Taiwan University Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Jul 2016 | Recruiting --> Completed | N=170 --> 112
- flucloxacillin sodium / Generic mfg.
New trial: FANATIC: Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients (clinicaltrials.gov) - Dec 15, 2016
P=N/A, N=30, Not yet recruiting, Sponsor: Radboud University
- Trial completion: TUBOGTEP: Positron Emission Tomography in Extrapulmonary Tuberculosis (clinicaltrials.gov) - Dec 13, 2016
P=N/A, N=55, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Trial primary completion date: Dec 2016 --> Jul 2016 | Recruiting --> Completed | N=170 --> 112 Active, not recruiting --> Completed
- Trial primary completion date: Simplified GBS Screening and Prevalence of ESBL in Pregnant Women (clinicaltrials.gov) - Dec 13, 2016
P=N/A, N=480, Recruiting, Sponsor: University Hospital, Basel, Switzerland
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial primary completion date: Systems Biology of PNEUMOVAX®23 and PREVNAR 13® (clinicaltrials.gov) - Dec 12, 2016
P=N/A, N=88, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Nov 2016 --> Dec 2017
- ||| New trial, Diagnostic assay: Diagnosis of Bacteremia/Septicemia and Culture Negative Endocarditis by the Karius Sequencing-Based Infectious Disease Diagnostic Assay (clinicaltrials.gov) - Dec 9, 2016
P=N/A, N=105, Recruiting, Sponsor: Karius, Inc.
- rifampicin / Generic mfg.
Enrollment closed, Trial primary completion date: High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study (clinicaltrials.gov) - Dec 9, 2016
P2b, N=60, Active, not recruiting, Sponsor: Universitas Padjadjaran
Trial primary completion date: Nov 2016 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> May 2017
- New trial: Ecological Effect of Arginine Dentifrice on Oral Microbiota (clinicaltrials.gov) - Dec 9, 2016
P=N/A, N=42, Completed, Sponsor: Sichuan University
- | New P1/2 trial, Head-to-Head: Line Probe Assay Evaluation Study (clinicaltrials.gov) - Dec 7, 2016
P1/2, N=888, Completed, Sponsor: Foundation for Innovative New Diagnostics, Switzerland
- vancomycin / Generic mfg.
Trial primary completion date: RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates (clinicaltrials.gov) - Dec 6, 2016
P=N/A, N=200, Recruiting, Sponsor: Murdoch Childrens Research Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> May 2017 Trial primary completion date: Sep 2017 --> Dec 2017
- |||| Trial completion, Enrollment change, Trial primary completion date: Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication (clinicaltrials.gov) - Dec 6, 2016
P4, N=199, Completed, Sponsor: Asan Medical Center
Trial primary completion date: Sep 2017 --> Dec 2017 Recruiting --> Completed | N=150 --> 199 | Trial primary completion date: Jul 2009 --> May 2010
- Trial completion, Trial primary completion date: Helicobacter Pylori and Proton Pump Inhibitor (clinicaltrials.gov) - Dec 6, 2016
P=N/A, N=30, Completed, Sponsor: Asan Medical Center
Recruiting --> Completed | N=150 --> 199 | Trial primary completion date: Jul 2009 --> May 2010 Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Dec 2016
- ||| Enrollment open: A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years (clinicaltrials.gov) - Dec 5, 2016
P1, N=66, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- Trial completion, Trial initiation date: Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction (clinicaltrials.gov) - Dec 5, 2016
P4, N=106, Completed, Sponsor: Medical University of Vienna
Not yet recruiting --> Recruiting Recruiting --> Completed | Initiation date: Jan 2014 --> Jan 2012
- taniborbactam (VNRX-5133) / VenatoRx
Enrollment open: VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers (clinicaltrials.gov) - Dec 3, 2016
P1, N=92, Recruiting, Sponsor: VenatoRx Pharmaceuticals, Inc.
Recruiting --> Completed | Initiation date: Jan 2014 --> Jan 2012 Not yet recruiting --> Recruiting
- ||| Trial completion, Enrollment change: RAMPED: Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections (clinicaltrials.gov) - Dec 2, 2016
P=N/A, N=2298, Completed, Sponsor: Connie Price
Not yet recruiting --> Recruiting Recruiting --> Completed | N=20000 --> 2298
- Enrollment change, Trial withdrawal, Trial primary completion date: POPH: Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population (clinicaltrials.gov) - Dec 2, 2016
P0, N=0, Withdrawn, Sponsor: Université de Montréal
Recruiting --> Completed | N=20000 --> 2298 N=621 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Feb 2016 --> Jun 2016
- vancomycin / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients (clinicaltrials.gov) - Dec 1, 2016
P4, N=44, Completed, Sponsor: Massachusetts General Hospital
N=621 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Feb 2016 --> Jun 2016 Recruiting --> Completed | N=120 --> 44 | Trial primary completion date: Jul 2015 --> Nov 2016
- ||||||| Trial completion, Phase classification: Combined Study - Phase 3b MenB Long Term Persistence in Adolescents (clinicaltrials.gov) - Dec 1, 2016
P3b, N=530, Completed, Sponsor: Novartis Vaccines
Recruiting --> Completed | N=120 --> 44 | Trial primary completion date: Jul 2015 --> Nov 2016 Recruiting --> Completed | Phase classification: P3 --> P3b